PE20110345A1 - Anticuerpos contra la il17 humana - Google Patents

Anticuerpos contra la il17 humana

Info

Publication number
PE20110345A1
PE20110345A1 PE2011000642A PE2011000642A PE20110345A1 PE 20110345 A1 PE20110345 A1 PE 20110345A1 PE 2011000642 A PE2011000642 A PE 2011000642A PE 2011000642 A PE2011000642 A PE 2011000642A PE 20110345 A1 PE20110345 A1 PE 20110345A1
Authority
PE
Peru
Prior art keywords
seq
region
antibody
antibodies against
against human
Prior art date
Application number
PE2011000642A
Other languages
English (en)
Inventor
Johannes Auer
Nikolaos Dimoudis
Guy Georges
Petra Hanke
Hendrik Knoetgen
Claire Louise Langrish
Ekkehard Moessner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of PE20110345A1 publication Critical patent/PE20110345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)

Abstract

REFERIDA A UN ANTICUERPO QUE SE UNE A LA IL-17 HUMANA QUE COMPRENDE: a) UN DOMINIO VARIABLE DE CADENA LARGA QUE CONTIENE UNA REGION CDR3 DE LA SEQ ID NO: 1, UNA REGION CDR2 DE LA SEQ ID NO: 2 O 9 Y UNA REGION CDR1 DE LA SEQ ID NO: 3 Y b) UN DOMINIO VARIABLE DE CADENA CORTA QUE CONTIENE UNA REGION CDR3 DE LA SEQ ID NO:4, UNA REGION CDR2 DE LA SEQ ID NO:5 Y UNA REGION CDR1 DE LA SEQ ID NO:6, DONDE EL ANTICUERPO ES UN ANTICUERPO QUIMERICO, HUMANIZADO O ES UNA VARIANTE DEL ANTICUERPO 3C1 DESPROVISTO DEL EPITOPE DE CELULA T. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA, UN VECTOR, UN ACIDO NUCLEICO Y UNA LINEA CELULAR DE HIBRIDOMAS
PE2011000642A 2008-09-29 2009-09-21 Anticuerpos contra la il17 humana PE20110345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08017155 2008-09-29

Publications (1)

Publication Number Publication Date
PE20110345A1 true PE20110345A1 (es) 2011-06-13

Family

ID=40352697

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000642A PE20110345A1 (es) 2008-09-29 2009-09-21 Anticuerpos contra la il17 humana

Country Status (26)

Country Link
US (2) US8003099B2 (es)
EP (1) EP2331575B1 (es)
JP (2) JP5581323B2 (es)
KR (1) KR101318549B1 (es)
CN (2) CN102164959A (es)
AR (1) AR073692A1 (es)
AU (1) AU2009296299A1 (es)
BR (1) BRPI0919531A2 (es)
CA (1) CA2737636A1 (es)
CL (1) CL2011000672A1 (es)
CO (1) CO6351795A2 (es)
CR (1) CR20110161A (es)
EC (1) ECSP11010911A (es)
ES (1) ES2493042T3 (es)
HK (1) HK1171458A1 (es)
IL (1) IL211684A0 (es)
MA (1) MA32725B1 (es)
MX (1) MX2011003184A (es)
MY (1) MY153893A (es)
NZ (1) NZ591484A (es)
PE (1) PE20110345A1 (es)
RU (1) RU2539029C2 (es)
TW (1) TWI393570B (es)
UA (1) UA103499C2 (es)
WO (1) WO2010034443A1 (es)
ZA (1) ZA201102004B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
AU2011285922B2 (en) * 2010-08-05 2016-06-16 Anaptysbio, Inc. Antibodies directed against IL-17
EP2625199B1 (en) * 2010-10-08 2017-11-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
EP3111954B1 (en) 2010-11-05 2019-04-03 Novartis Ag Methods of treating ankylosing spondylitis using anti-il-17 antibodies
WO2012076442A1 (en) 2010-12-07 2012-06-14 F. Hoffmann-La Roche Ag Adapter for the non-invasive cultivation of cells and uses thereof
MX345885B (es) 2010-12-07 2017-02-22 Hoffmann La Roche Dispositivo de mezclado de alimentacion y su uso.
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
CN102188707B (zh) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 Il-17抑制剂在制备治疗流感的药物中的用途
WO2012123488A1 (en) 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104011223A (zh) 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2013158821A2 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
EP3590537A1 (en) 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MA38322B1 (fr) * 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
PT3072905T (pt) * 2013-11-18 2020-09-17 Shanghai hengrui pharmaceutical co ltd Agente de ligação a il-17a e suas utilizações
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
PT3122775T (pt) 2014-03-26 2019-12-26 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
AU2015313827C1 (en) 2014-09-10 2018-08-30 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
JP6858181B2 (ja) 2015-10-02 2021-04-14 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
WO2017055613A2 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018050028A1 (zh) * 2016-09-14 2018-03-22 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN109206515B (zh) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 一种全人源抗人白介素17a抗体及其应用
EP3703819A1 (en) 2017-11-02 2020-09-09 Novartis AG Method of treating tendinopathy using interleukin-17 (il-17) antagonists
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
CN111699006B (zh) * 2018-02-12 2021-08-24 原启生物科技(上海)有限责任公司 Il17抗体及其应用
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2019218298A1 (zh) * 2018-05-17 2019-11-21 江苏荃信生物医药有限公司 抗人白介素17a单克隆抗体及其应用
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
CN114728060A (zh) 2019-11-19 2022-07-08 诺华股份有限公司 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
CN114746444A (zh) 2019-12-06 2022-07-12 诺华股份有限公司 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US5716623A (en) 1994-12-07 1998-02-10 Immunex Corporation Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
US6063372A (en) 1995-10-27 2000-05-16 Inserm, Institut National De La Sante Et De La Recherche Medicale Uses of mammalian CTLA-8 and related reagents
PT862454E (pt) 1995-10-27 2002-11-29 Inst Nat La Sante Et La Rech M Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
US6271014B1 (en) 1998-01-09 2001-08-07 Schering-Plough Mammalian proteinases; related reagents and methods
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
CN1341660A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人白细胞介素受体－配体(il－17b和il－17br)32.56和编码这种多肽的多核苷酸
SI1983000T1 (sl) 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7838638B2 (en) * 2005-12-13 2010-11-23 Eli Lilly And Company Anti-IL-17 antibodies
EP1984401A2 (en) * 2006-01-31 2008-10-29 Novartis AG Il-17 antagonistic antibodies fpr treating cancer
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
WO2008002115A1 (fr) 2006-06-27 2008-01-03 Vladimir Guzenko Appareil hydraulique à membrane transformant la force de gravitation en couple de torsion destiné à un moteur sans carburant et moteur correspondant
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
MX2009001620A (es) * 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof

Also Published As

Publication number Publication date
US8003099B2 (en) 2011-08-23
IL211684A0 (en) 2011-06-30
RU2011116927A (ru) 2012-11-10
MX2011003184A (es) 2011-04-21
KR20110048572A (ko) 2011-05-11
TW201023882A (en) 2010-07-01
US20130195844A1 (en) 2013-08-01
ZA201102004B (en) 2011-12-28
RU2539029C2 (ru) 2015-01-10
NZ591484A (en) 2012-09-28
CN102617735A (zh) 2012-08-01
EP2331575B1 (en) 2014-05-28
CO6351795A2 (es) 2011-12-20
MY153893A (en) 2015-04-15
KR101318549B1 (ko) 2013-10-16
TWI393570B (zh) 2013-04-21
EP2331575A1 (en) 2011-06-15
CR20110161A (es) 2011-04-27
JP5581323B2 (ja) 2014-08-27
JP2014128279A (ja) 2014-07-10
AU2009296299A1 (en) 2010-04-01
BRPI0919531A2 (pt) 2015-12-08
AR073692A1 (es) 2010-11-24
ES2493042T3 (es) 2014-09-11
CN102617735B (zh) 2015-09-09
WO2010034443A1 (en) 2010-04-01
HK1171458A1 (en) 2013-03-28
CN102164959A (zh) 2011-08-24
CA2737636A1 (en) 2010-04-01
UA103499C2 (ru) 2013-10-25
MA32725B1 (fr) 2011-10-02
ECSP11010911A (es) 2011-05-31
JP2012503977A (ja) 2012-02-16
US20100080812A1 (en) 2010-04-01
CL2011000672A1 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
PE20110345A1 (es) Anticuerpos contra la il17 humana
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
PE20121542A1 (es) Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados
PH12018501548A1 (en) Bispecific t cell engaging antibody constructs
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20140247A1 (es) Anticuerpos anti-cd38
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
PE20180499A1 (es) Anticuerpos de union a tau
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20130206A1 (es) Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
PE20140825A1 (es) Anticuerpos contra il-6 y sus usos
PE20141017A1 (es) Anticuerpos del cea
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.

Legal Events

Date Code Title Description
FC Refusal